Plus Therapeutics Announces Positive Interim Data from ReSPECT Phase 1 Clinical Trial in Recurrent Glioblastoma (GlobeNewswire) - Nov 19, 2020 - P1, N=55; ReSPECT (NCT01906385); Sponsor: Plus Therapeutics; "Plus Therapeutics, Inc....announced positive new interim data from its ongoing ReSPECT™ Phase 1 clinical trial evaluating the Company's lead investigational asset, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma...All 15 patients in the first five of six planned cohorts have completed treatment; RNL treatment volume and radiation dose increased successfully from 0.66 milliliter (mL) to 8.8 mL and 1.0 millicurie (mCi) to 22.3 mCi, respectively."
P1 data • Glioblastoma • Oncology
|